<DOC>
	<DOCNO>NCT00083044</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development treat early cancer . Diagnostic procedure , ductal lavage , may improve ability ass effectiveness chemopreventive drug , tamoxifen , breast cell may help doctor plan effective treatment . PURPOSE : This phase II trial study well ductal lavage work assess change breast cell woman early breast cancer high risk develop breast cancer eligible tamoxifen therapy .</brief_summary>
	<brief_title>Ductal Lavage Assessing Women With Early Breast Cancer High Risk Developing Breast Cancer Who Are Eligible For Tamoxifen Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate cell morphology protein expression breast epithelial cell ductal lavage sample marker tamoxifen effect woman breast cancer woman high risk develop breast cancer . - Evaluate methylation status gene previously identify relate neoplastic progression cell ductal lavage sample participant . - Evaluate protein profile nipple aspiration fluid participant treatment tamoxifen . OUTLINE : This multicenter study . Participants eligible tamoxifen chemoprevention therapy undergo ductal lavage . Participants inform cytological finding choose receive oral tamoxifen daily 5 year vs observation . All participant undergo repeat ductal lavage 6 month . Participants atypical cytology undergo third ductal lavage 12 month . Mammographic density measure study entry 12 month . Ductal cell analyze methylation status candidate gene . Participants follow clinically indicate . PROJECTED ACCRUAL : A total 200 participant accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Diagnosis small invasive breast cancer Diagnosis ductal lobular carcinoma situ breast At high risk breast cancer ( 5year Gail model risk &gt; 1.6 % ) Eligible tamoxifen therapy No plan adjuvant chemotherapy Prior unilateral early breast cancer allowed* NOTE : *Only unaffected breast examine study Hormonereceptor status : Estrogen receptorpositive ( patient small invasive breast cancer ) PATIENT CHARACTERISTICS : Age 18 64 Sex Female Menopausal Status Premenopausal postmenopausal Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No prior venous thromboembolism Other At least 12 month postpartum Not pregnant Not nurse within past 12 month No know allergy lidocaine , prilocaine , bupivacaine No uterine hyperplasia polyps No contraindication tamoxifen PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 6 month since prior chemotherapy Endocrine therapy Concurrent hormonereplacement therapy allow Prior tamoxifen raloxifene allow provide treatment duration 6 month At least 1 year since prior raloxifene Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>